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Summary
 
Non-expensive and low-complexity surrogate markers for monitoring the
response to combined antiretroviral therapy (combined-ART) are needed in
poor-resource settings where routine assessment of CD4+
 
 T-lymphocyte
count and viral load can not be afforded. We longitudinally evaluated Ig
serum levels in 234 HIV-1 infected children receiving combined-ART with ≥
 
 3
drugs. Since Ig levels physiologically vary with age, differences at different age
periods were evaluated as differences in z-scores calculated using the mean
and standard deviation of the normal population for each age period. Data
from 17 (7·3%) children with immunological failure and from 54 (23·1%)
children with  virological  failure  of  combined-ART  were  compared  with
data  from  not-failed children. At baseline children with immunological fail-
ure showed higher IgM 
 
z
 
-scores (
 
P
 
 =
 
 0·042) than children without. After 3–
12 months of therapy immunologically failed children displayed higher viral
loads (
 
P
 
 <
 
 0·0001) and IgA (
 
P =
 
 0·043) 
 
z
 
-scores than not-failed children. Sim-
ilarly, at the same follow-up time, children with virological failure showed
lower CD4
 
+
 
 T-lymphocyte percentages (
 
P
 
 =
 
 0·005) and higher IgA 
 
z
 
-scores
(
 
P
 
 <
 
 0·0001) than not-failed children. No difference in IgG or IgM 
 
z
 
-scores was
evidenced between failed and not-failed children after 3–12 months of ther-
apy. In conclusion, IgA serum level is a cheap and low-complexity marker of
immunological or virological failure of combined-ART which might be
adopted in poor-resource settings.
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Introduction
 
Before the introduction of combined-antiretroviral therapy
(combined-ART) elevated serum levels of immunoglobulins
(Ig) G, IgM, and IgA have been reported in adults [1] and
children [2,3] with human immunodeficiency type 1 virus
infection (HIV-1). Ig produced in excess are due to the poly-
clonal expansion of B-lymphocytes, are not antigen-specific
and are ineffective in protecting against infections [4,5]. Pre-
vious studies demonstrated that in adults Ig serum levels
decreased during effective antiretroviral therapy [6–10].
These data suggest that Ig serum levels could represent not
expensive and low-complexity markers for monitoring
response to combined antiretroviral therapy (combined-
ART) which could be adopted in poor-resource settings
where routine assessment of CD4
 
+
 
 T-lymphocyte count and
viral load can not be afforded [10].
To evaluate the impact of combined-ART on Ig serum
levels in the paediatric setting, we longitudinally evaluated
children with perinatal HIV-1 infection treated with
combined-ART, divided on the basis of their immunological
or virological response to antiretroviral therapy.
 
Methods
 
Data collection
 
Data were collected by the Italian Register for HIV Infection
in Children, which is a nationwide multicentre study of chil-
dren perinatally exposed to HIV-1 instituted in 1985 by the
Italian Association of Paediatrics [11]. The data source is a
network of 106 paediatric clinics distributed throughout
Italy. The data are transmitted to the two coordinating cen-
tres at Department of Paediatrics of the Universities of
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Florence and Turin. Information concerning data collection
has been described in detail elsewhere [11,12]. Briefly, data
on clinical condition, treatment, viral load, lymphocyte
count and Ig serum levels were collected every 6–12 months.
Data were collected prospectively and then entered into a
specific database at the coordinating centres. In the present
study data collected from January 1st, 1996 up to December
31st, 2002 were analysed.
Clinical HIV-1 stage was classified according to the rec-
ommendations laid down by the Centers for Disease Control
and Prevention (CDC) [13]. Infection was defined by the
persistence of HIV-1 antibodies after 18 months of life or by
the detection
 
,
 
 on at least 2 occasions
 
,
 
 of virus markers
(proviral DNA, virus culture, free or complexed p24 antige-
naemia). Laboratory analyses were performed locally, using
the same standardized methods. Ig levels were measured by
laser nephelometry. Viral loads were evaluated quantitatively
by Amplicor HIV Monitor test and results are expressed as
Log
 
10
 
 HIV-1 RNA copies/ml. CD4
 
+
 
 T-lymphocyte counts
were measured using the standardized fluorescent-activated
cell sorting technique. According to the USA guidelines for
the use of antiretroviral agents in paediatric HIV infection
[14], CD4
 
+
 
 T-lymphocyte percentages, rather than their
absolute counts, were taken into account as these percentages
reflect the immune status of HIV-1 infected children more
accurately. This study was approved by review boards and
ethics committees of the participating institutions.
 
Treatment
 
The specific therapy offered was left to the discretion of the
participating centres and was based upon clinical and labo-
ratory evaluations [11]. The criteria adopted were those
discussed and agreed upon during annual meetings of par-
ticipating centres [11] and those of the CDC [15] and the
Italian [16] paediatric guidelines for antiretroviral therapy in
children.
 
Patients
 
Children were included in the study if the following condi-
tions were satisfied:
• treatment with 
 
≥ 
 
3 drugs, including at least one protease
inhibitor or one non-nucleoside reverse transcriptase
inhibitor, for at least 3 months;
• no treatment with intravenous Ig. The children should
have received 
 
≥
 
 3 drugs during the entire follow-up period,
but the drugs could have been changed over time.
Children were divided in two groups according to immu-
nological response to combined-ART. Immunological failure
was defined, on the basis of the USA [14] and the Italian
guidelines [16], by a 
 
≥
 
 5% decrease in CD4
 
+
 
 T-lymphocyte
percentage  after  3–12 months  of  antiretroviral  therapy
(if baseline value was 
 
£
 
 15%) or by a change in the CDC
immunological category (if baseline CD4
 
+
 
 T-lymphocyte
percentage was 
 
>
 
 15%). Additional analyses were performed
considering children with or without virological failure of
combined-ART. Virological failure was defined was defined
by a reduction of viral load 
 
<
 
 1·0 log
 
10
 
 RNA copies/ml after
3–12 months of therapy [14,16].
 
Statistical analysis
 
Ages were expressed as median and range. Since Ig levels
physiologically vary with age, differences at different age
periods were evaluated as differences in 
 
z-
 
scores calculated
using the formula:
(patient’s Ig level 
 
-
 
 mean Ig level in healthy population 
of corresponding age class)/standard deviation in healthy 
population of corresponding age class) 
 
[2].
 
Considering altogether data from children of all the age
classes Ig values are not normally distributed, since they are
skewed to higher levels in early life [2]. Nevertheless, values
are normally distributed within each considered age class [2].
Additional analyses by using the Kolgorov-Smirnov test for
normality confirmed our data to be normally distributed
within each considered age class. Therefore, the used formula
to calculate z-scores, which assumes an underlying normality
of the variable, was applicable. Means and standard devia-
tions for healthy population for each age period were calcu-
lated using values from a previous study by de Martino and
colleagues on 373 healthy children born in different areas of
Italy [2]. Viral loads, CD4
 
+
 
 T-lymphocyte percentages, and Ig
 
z
 
-scores were expressed as means and standard deviations.
The paired Student’s 
 
t
 
-test was used to evaluate changes in
viral loads, CD4
 
+
 
 T-lymphocyte percentages, and Ig 
 
z-
 
scores
over time. The Student’s 
 
t
 
-test was used to assess differences
between children with or without immunological or virolog-
ical failure. Measures of sensitivities and specificities for
stated levels of IgA have been calculated by receiver-operating
characteristic (ROC) plots. ROC analyses were used to iden-
tify cut off values of IgA z-score that could be useful in dis-
tinguishing immunological or virological failure.
The statistical analyses were performed using the SPSS
software package (SPSS 11·5; Chicago, IL, USA). 
 
P
 
 
 
<
 
 0·05
was considered statistically significant.
 
Results
 
Information on Ig levels both at baseline and at 3–12 months
after the beginning of combined-ART was available for 234
children receiving 
 
≥
 
 3 drugs (median age 6·9 years; range
0·1–17·0).
 
Ig z-scores in children with or without immunological 
failure after 3–12 months of combined-ART
 
Seventeen out of the 234 study children (7·3%) showed
immunological failure after 3–12 months of combined-ART.
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Ig 
 
z-
 
scores in children with or without immunological fail-
ure are given in Table 1. Obviously, CD4
 
+
 
 T-lymphocyte
percentage significantly (
 
P
 
 
 
<
 
 0·0001) decreased in children
with immunological failure and increased in those without
(
 
P
 
 
 
=
 
 0·004). Viral load significantly decreased in children
without (
 
P
 
 
 
<
 
 0·0001), but not in those with immunological
failure. At baseline children with subsequent immunological
failure exhibited higher IgM 
 
z
 
-scores (
 
P
 
 
 
=
 
 0·042 
 
versus
 
 not-
failed children). After 3–12 months of therapy immunolog-
ically failed children displayed higher viral loads (
 
P
 
 
 
<
 
 0·0001
 
versus
 
 not-failed children) and IgA 
 
z-
 
scores (
 
P
 
 
 
=
 
 0·043 
 
versus
 
not-failed children). IgA z-score threshold value of 5·03 was
associated with sensitivity of 79·5% and specificity of 59·2%
in predicting immunological failure.
 
Ig z-scores in children with or without virological failure 
after 3–12 months of combined-ART
 
Fifty-four (27·1%) of 234 study children showed virological
failure after 3–12 months of combined-ART (Table 1). Obvi-
ously, viral load significantly decreased in children without
(
 
P
 
 
 
<
 
 0·0001), but not in those with virological failure
(
 
P
 
 
 
=
 
 0·870). CD4
 
+
 
 T-lymphocyte percentages increased in
the former (
 
P
 
 
 
<
 
 0·0001) but not in the latter children
(
 
P
 
 
 
=
 
 0·421). No difference in Ig 
 
z
 
-scores were observed at
baseline between children with or without subsequent viro-
logical failure. After 3–12 months of combined-ARV chil-
dren with virological failure showed higher IgA 
 
z
 
-scores
(7·51 
 
±
 
 11·97 
 
versus
 
 3·37 
 
±
 
 5·38; 
 
P
 
 
 
<
 
 0·0001) but not IgG or
IgM 
 
z
 
-scores. IgA z-score threshold value of 3·53 was asso-
ciated with sensitivity of 72·5% and specificity of 66·6% in
predicting virological failure.
 
Discussion
 
In this study children with immunological or virological fail-
ure of combined-ART with 
 
≥
 
 3 drugs were evaluated longi-
tudinally. Baseline IgM 
 
z
 
-scores predicted immunological
but not virological outcome to combined-ART. After 3–
12 months, children with immunological or virological fail-
ure displayed lower CD4
 
+
 
 T-lymphocyte percentages, higher
viral loads and higher IgA, but not IgG or IgM, 
 
z
 
-scores than
those without.
To our knowledge, this is the first study on the meaning of
Ig serum levels as markers of response to combined-ARV in
HIV-1 infected children. Our results confirm Ig z-scores to be
elevated in HIV-1 perinatally infected children, as previously
described [2]. In not-failed children, the reduction of Ig lev-
els, paralleled by the restoration of CD4
 
+
 
 T-lymphocyte per-
centages and reduction in viral loads, is probably to be
ascribed to the restoration of T-lymphocyte functions [17]
and recovery of the T-B lymphocyte cooperation. Consistent
with this, other studies in adults [6–10] reported B-lympho-
cyte function restoration and significant decreases in Ig serum
levels during effective combined-ART. Results similar to ours
have been reported by Katzenstein and colleagues [18] who
found that adult patients experiencing good response to com-
bined-ART had lower IgA, but not IgG or IgM, levels than
patients without. On the contrary, in one report [19] no
change in IgA but a decrease in IgM levels in adult patients
with virological response to therapy was described.
Some observations suggest that, in children, IgA serum
levels reflect the progression of HIV-1 infection more accu-
rately than IgG or IgM levels [2]. Indeed, we previously
demonstrated that in children with unfavourable clinical
 
Table 1.
 
Features and Ig z-scores in children with and without immunological or virological failure of combined-ART.
Immunological response Virological response
Not-failed Failed
 
P
 
-value Not-failed Failed
 
P
 
-value
 
n
 
 (children) 217 17 180 54
CD4
 
+
 
 T-lymphocytes (%)*
baseline 17·75 
 
± 
 
11·86 20·99 
 
± 
 
6·51 0·326 21·53 
 
± 
 
11·3 21·49 
 
± 
 
11·63 0·982
3–12 months 24·04 
 
± 
 
10·93§ 14·07 
 
± 
 
6·44†
 
<
 
0·0001 27·65 
 
± 
 
9·51§ 23·33 
 
± 
 
11·00 0·005
Viral load (Log10 RNA copies/ml)*
baseline 4·68 
 
± 
 
0·96 4·41 
 
± 
 
0·34 0·251 4·88 
 
± 
 
0·76 4·37 ± 1·24 0·221
3–12 months 2·56 ± 1·59§ 4·16 ± 1·43 <0·0001 1·75 ± 1·74§ 4·41 ± 1·25 <0·0001
IgG z-score*
baseline 5·53 ± 4·37 5·09 ± 3·57 0·686 5·01 ± 5·04 5·87 ± 4·57 0·330
3–12 months 3·61 ± 2·78§ 3·56 ± 3·52 0·944 3·01 ± 2·09§ 3·53 ± 3·38‡ 0·174
IgM z-score*
baseline 7·36 ± 6·96 11·14 ± 11·51 0·042 6·20 ± 6·91 8·26 ± 7·14 0·096
3–12 months 4·62 ± 7·53§ 6·59 ± 7·24 0·299 3·01 ± 2·09§ 3·69 ± 4·59§ 0·297
IgA z-score*
baseline 8·51 ± 9·82 9·51 ± 13·58 0·695 5·86 ± 6·37 8·34 ± 12·55 0·070
3–12 months 6·59 ± 7·24§ 10·28 ± 12·05 0·043 3·37 ± 5·38§ 7·51 ± 11·97 <0·0001
Note: * mean ± standard deviation; § P < 0·0001 versus baseline; † P = 0·004 versus baseline; ‡ P = 0·003 versus baseline.
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evolution IgA alterations are the most pronounced ones [2],
and IgA serum levels has been proposed as a surrogate
marker of HIV infection in infants [1].
Induction of high-rate IgA class switching requires a set of
factors which must act synergistically to skew Ig production
predominantly toward IgA isotype [20]. At least 3 important
factors have been identified:
• engagement of CD40 on B cells by CD40 ligand (CD40L)
on Ag-activated CD4+ T cells which determines class
switch gene recombination [20];
• high  concentration  of  transforming  TGF-b.  TGF-b  is
a well-documented switch factor for IgA which induces
large increase in IgA secretion by CD40-activated B-
lymphocytes through its action on regulatory regions of
several CH genes [21];
• high concentration of type 2 cytokines including IL-4 and
IL-5. In particular TGF-b preferentially induces switching
to sIgA + B-lymphocytes while IL-5 induces the matura-
tion of postswitch sIgA + B-lymphocytes into IgA-
secreting cells in a stepwise fashion [22].
All these factors have been reported to be up-regulated in
HIV-1 infected individuals. Indeed
• abnormal CD40L expression has been described on T-
helper lymphocytes in HIV-1 infected children and its
baseline level correlated with serum IgA [23];
• HIV-1 gp160 induces TGF-b secretion which was found
elevated in the serum of HIV-1 infected patients with
advanced disease [24,25]);
• we [26] and others [27] previously demonstrated that, as
HIV disease progresses, balance of type 1 helper cytokines
(IL-2 and IFN-g) shift to a type 2 helper cytokine profile
(IL-4, IL-5, IL-6, and IL-10).
Therefore, we speculate that in children with failure of com-
bined-ARV depletion of CD4+ T-lymphocytes is paralleled
by a progressive impairment of the T-B cooperation and
increased expression of type 2 helper cytokines and TGF-b
resulting in elevated IgA production.
Not-expensive surrogate markers for monitoring response
to combined-ART are needed in poor-resource settings [28]
and, recently, the use of total lymphocyte count for moni-
toring response to therapy has been proposed [29]. Basing
on our results, IgA serum level is a cheap and low-complexity
marker of failure of combined-ART in children which may
be adopted in developing countries.
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